|
|
News Breaks | | | | January 31, 2013 | | 07:49 EDT |  | CLSN | Celsion Corp. volatility elevated into ThermoDox didn’t meet primary endpoint
Celsion Corp. overall option implied volatility of 224 is above its 26-week average of 121 according to Track Data, suggesting large price movement into the company saying Phase III HEAT study of ThermoDox did not meet primary endpoint. | |
|
News For CLSN From The Last 14 Days Check below for free stories on CLSN the last two weeks. |
|
|
| May 22, 2013 | | 08:03 EDT |  | CLSN | Celsion announces issurance of more patents covering ThermoDox technologies
Celsion announced that its proprietary patent application, "Method of Storing Nanoparticle Formulations," has now been granted in the four largest markets for liver cancer globally: China, Japan, South Korea and most recently Taiwan. Celsion holds an exclusive license agreement with Duke University for its temperature sensitive liposome technology which covers the ThermoDox formulation. Celsion's newly issued patents pertain specifically to methods of storing stabilized, temperature-sensitive liposomal formulations and will assist in the protection of global rights by extending the overall term of the ThermoDox patent portfolio to August 2026. | | | May 16, 2013 | | 07:28 EDT |  | CLSN | I/O Central to host a conference
 Subscribe for More Information | |
|
|
|
|
|
|
